We provide proof-of-concept that brain delivery of siRNA targeting human SNCA to intervene in the progression of aSyn pathology can be achieved by intranasal application of PEI- or PPI-based, chemically modified nanoparticles in the Thy1-aSyn mouse model of PD. Here, THY1 is linked to Parkinson disease.